TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. (TLSI) Revenue
Annual & quarterly revenue history · segment & region breakdown
TLSI · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsTriSalus Life Sciences, Inc. trailing twelve-month (TTM) revenue is $0.04B, an increase of 53.41% year-over-year from $0.05B in FY2025.
Revenue trend
2025 – 2020 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.05B | +$0.02B | +53.41% |
| 2024-12-31 | $0.03B | +$0.01B | +58.99% |
| 2023-12-31 | $0.02B | +$0.01B | +49.31% |
| 2022-12-31 | $0.01B | +$0.00B | +47.58% |
| 2021-12-31 | $0.01B | +$0.01B | — |
| 2020-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income TriSalus Life Sciences, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
TriSalus Life Sciences, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from TriSalus Life Sciences, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
TLSI revenue · 4 questionsTLSI's trailing twelve-month (TTM) revenue is $0.04B. That is an increase of 53.41% year-over-year from $0.05B in FY2025.
▸ Source: FMP · TriSalus Life Sciences, Inc. SEC filings · GAAP · TriSalus Life Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026